Your browser doesn't support javascript.
Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers.
Cocomazzi, Giovanna; Piazzolla, Valeria; Squillante, Maria Maddalena; Antinucci, Stefano; Giambra, Vincenzo; Giuliani, Francesco; Maiorana, Alberto; Serra, Nicola; Mangia, Alessandra.
  • Cocomazzi G; Liver Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo (Fg), Italy.
  • Piazzolla V; Liver Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo (Fg), Italy.
  • Squillante MM; Liver Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo (Fg), Italy.
  • Antinucci S; Allergy Diagnostic Section Euroimmun, 35127 Padova, Italy.
  • Giambra V; Institute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT) Fondazione "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo (Fg), Italy.
  • Giuliani F; ICT Innovation and Research Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo (Fg), Italy.
  • Maiorana A; GSSL Unit, Fondazione "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo (Fg), Italy.
  • Serra N; Department of Public Health, University "Federico II", 80131 Naples, Italy.
  • Mangia A; Liver Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo (Fg), Italy.
Vaccines (Basel) ; 9(8)2021 Aug 16.
Article in English | MEDLINE | ID: covidwho-1377009
ABSTRACT

PURPOSE:

Clinical significance and durability of serological response after mRNA COVID-19 vaccines is under investigation. Data on early virological response are limited. To iden-tify potential predictors of antibody durability, circulating antibody levels were longitudinally ex-plored in healthcare workers included in a follow-up program for SARS-CoV-2 infection. Meth-ods Subjects meeting the inclusion criteria signed an informed consent. Serum samples were col-lected at baseline, before the first BNT162b2 vaccine, at days 7, 21, 31, 90, and 180 days after the first dose. Serological evaluation was performed by QuantiVac Euroimmune anti-S1 antibody as-say. Only subjects followed-up until day 90 are here considered.

RESULTS:

Of 340 taken into consid-eration, 265 subjects were naive, and 75 COVID-19 experienced. The former showed a progres-sive increase in their antibody levels before day 90 decline, while the latter showed antibody levels reaching a plateau at day 7 and slightly declining at day 90. All showed antibody levels higher than the assay cut-off at day 31 and 90. Among naive, 108 had an early response whose predic-tors were younger age and female gender (OR 0.94, 95% CI 0.91-0.96, p < 0.0001; and OR 2.58, 95% CI 1.48-4.51, p = 0.0009). Naive subjects experienced a day 30/90 decline in antibody levels, whereas experienced did not. Early response was an independent predictor of higher day 30/90 antibody levels decline (OR = 2.05, 95% CI 1.04-4.02; p = 0.037).

CONCLUSIONS:

Our results suggest that in healthcare workers early response might be inversely associated with antibody levels 90 days after BNT162b2 vaccine.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Prognostic study Topics: Vaccines Language: English Year: 2021 Document Type: Article Affiliation country: Vaccines9080913

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Prognostic study Topics: Vaccines Language: English Year: 2021 Document Type: Article Affiliation country: Vaccines9080913